Get the Stockscreener App
2.02
1.00%
0.02
After Hours:
1.99
-0.03
-1.49%
Milestone Pharmaceuticals Inc stock is traded at $2.02, with a volume of 971.07K.
It is up +1.00% in the last 24 hours and down -10.22% over the past month.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
See More
Previous Close:
$2.00
Open:
$1.99
24h Volume:
971.07K
Relative Volume:
1.81
Market Cap:
$107.72M
Revenue:
-
Net Income/Loss:
$-59.69M
P/E Ratio:
-1.4532
EPS:
-1.39
Net Cash Flow:
$-46.54M
1W Performance:
-1.46%
1M Performance:
-10.22%
6M Performance:
+37.41%
1Y Performance:
+21.69%
1-Day Range:
$1.965
$2.06
1-Week Range:
$1.92
$2.13
52-Week Range:
$1.12
$2.75
Milestone Pharmaceuticals Inc Stock (MIST) Company Profile
Name
Milestone Pharmaceuticals Inc
Sector
Industry
Phone
(514) 336-0444
Address
1111 BOUL. DR.-FREDERIK-PHILIPS, STE 420, MONTREAL, QC
Compare MIST with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIST
Milestone Pharmaceuticals Inc
|
2.02 | 107.72M | 0 | -59.69M | -46.54M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Milestone Pharmaceuticals Inc Stock (MIST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-20-23 | Downgrade | Jefferies | Buy → Hold |
| Apr-22-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-05-21 | Initiated | H.C. Wainwright | Buy |
| Jul-29-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-24-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-25-20 | Downgrade | Jefferies | Buy → Hold |
| Mar-24-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-24-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-04-19 | Initiated | Oppenheimer | Outperform |
| Jun-03-19 | Initiated | Cowen | Outperform |
| Jun-03-19 | Initiated | Jefferies | Buy |
| Jun-03-19 | Initiated | Piper Jaffray | Overweight |
View All
Milestone Pharmaceuticals Inc Stock (MIST) Latest News
HC Wainwright Has Pessimistic Outlook of MIST Q1 Earnings - Defense World
Milestone Pharma Faces FDA Decision In MarchWill It Mean Heartbreak Or Happiness For Investors? - RTTNews
What is HC Wainwright's Estimate for MIST Q1 Earnings? - MarketBeat
FY2029 Earnings Estimate for MIST Issued By HC Wainwright - Defense World
Milestone gears up for CARDAMYST launch in 2025 - Investing.com
Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC - The Manila Times
Game-Changing Heart Treatment Could Hit Market in 2025: Inside Milestone's Launch Strategy - StockTitan
Milestone Pharmaceuticals (NASDAQ:MIST) Receives “Buy” Rating from HC Wainwright - Defense World
H.C. Wainwright maintains $25 target on Milestone shares - MSN
Milestone Pharmaceuticals' (MIST) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Shuttle Pharmaceuticals Hits Milestone in Patient Enrollment for Phase 2 Clinical Trial - Defense World
Medexus Secures FDA Approval for GRAFAPEX, Eyes $100M Revenue Milestone - TipRanks
Shuttle Pharma Reaches Milestone in Patient Enrollment for - GlobeNewswire
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma - The Manila Times
Dogwood Therapeutics Poised For Data Milestone In Chemotherapy-Induced Neuropathic Pain In 2H 2025 - RTTNews
This Data Shows Just How Strong Milestone Pharmaceuticals Inc (NASDAQ: MIST) Stock Is - Stocks Register
NRx Pharmaceuticals Advances Towards FDA Approval with Key Stability Milestone for NRX-100 - MSN
Acadia Pharmaceuticals: Billion-Dollar Milestone and Global Expansion in 2025 - Yahoo Finance
Acadia Pharma Targets $1B Sales Milestone in 2025, Expands DAYBUE to European Market - StockTitan
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology - The Manila Times
Xenon Pharmaceuticals Sets Sights on Key 2025 Milestones - TipRanks
Rakovina Therapeutics Announces Key Milestone in Cancer Drug Innovation in Collaboration with Variational AI - GlobeNewswire
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones - Yahoo Finance
MimiVax and UI Pharmaceuticals Achieve Milestone in SurVaxM Production for Glioblastoma Treatment - BioSpace
Goa to Lead in Pharma Growth as Zlata Pharma Sets Industry Milestones - Yahoo Finance
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Milestone Pharmaceuticals Awards 113,000 Stock Options to New Key Employees - StockTitan
Milestone Pharmaceuticals (NASDAQ:MIST) Trading Down 8.1% – Time to Sell? - Defense World
Milestone Pharmaceuticals Inc (NASDAQ: MIST): An Enticing Stock To Watch - Stocks Register
Hemogenyx Pharmaceuticals achieves new milestone with patient recruitment for first clinical trial - Proactive Investors USA
MIST Stock Hits 52-Week High at $2.42 Amid Positive Momentum - Investing.com Australia
Tonix Pharmaceuticals achieves key milestone with FDA review timeline for innovative Fibromyalgia treatment - Proactive Investors USA
Ionis gets a milestone approval; Another top FDA official to step down - BioPharma Dive
MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development - AccessWire
Tonix Pharma’s TNX-102 SL Nears FDA Approval Milestone - TipRanks
Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of Cd228 X 4-1Bb Bispecific Molecule (Mabcalin Sgn-Bb228 (Prs-346) - Marketscreener.com
Novartis Ag ADR (NVS-N) QuotePress Release - The Globe and Mail
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for PLUVICTO™ - Barchart
Jazz Pharmaceuticals Marks International Volunteers Day with Corporate Impact Milestone - StockTitan
Medigene Receives Milestone Payment from Regeneron Pharmaceuticals, Inc. - Marketscreener.com
Candel therapeutics chief medical officer sells $63,482 in stock - Investing.com
Medexus and medac Conclude Negotiations to Amend US Treosulfan Agreement, Setting Regulatory Milestone Amounts and Payment Schedule - Newsfile
Sudden Hearing Loss Study Reaches Milestone: AudioCure Pharma Enrolls More Than Half of the Patients in AC102 Study - Yahoo Finance
Milestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright - MSN
Milestone Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Rare milestone for Canadian biotech as Zymeworks-developed drug gets FDA approval - The Globe and Mail
FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework - Benzinga
Update on Clinical MilestoneCytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies - Yahoo Finance
Seres Therapeutics Q3 2024 Earnings Preview - MSN
Milestone Pharmaceuticals Inc Stock (MIST) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):